Persistent/Recurrent Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis

Kim, Taek Min; Kim, Ji Hoon; Yoo, Roh Eul; Kim, Soo Chin; Chung, Eun Jae; Hong, Eun Kyoung; Jo, Sang-Won; Kang, Koung Mi; Choi, Seung Hong; Sohn, Chul Ho; Rhim, Jung Hyo; Park, Sun Won; Park, Young Joo

doi:10.1089/thy.2018.0151

Cited by 10 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as the average time to recurrence has been reported to range from 6 months to several decades 4,13,14 , several studies have accepted that PD is also a factor in recurrence 8,12 . The following factors are associated with the risk of recurrence (without structural disease) after initial surgery: lymph node metastasis, histological findings, tumor size, extrathyroidal and extranodal 8,12 . We found that PD developed in 67.3% of patients who did not undergo neck dissection, strongly suggesting that improvements in preoperative CT assessment and initial surgery are essential.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, all reoperations performed after initial therapy are considered to reflect recurrence. However, as the average time to recurrence has been reported to range from 6 months to several decades 4 , 13 , 14 , several studies have accepted that PD is also a factor in recurrence 8 , 12 . The following factors are associated with the risk of recurrence (without structural disease) after initial surgery: lymph node metastasis, histological findings, tumor size, extrathyroidal and extranodal extensions, sex, and age at diagnosis 2 , 9 – 11 .…”

Section: Discussionmentioning

confidence: 99%

“…It is clear that PD developing after DTC surgery reflects inadequate initial surgery. Several studies have identified parameters contributing to the risk of disease persistence 8 , 12 . We found that PD developed in 67.3% of patients who did not undergo neck dissection, strongly suggesting that improvements in preoperative CT assessment and initial surgery are essential.…”

Section: Discussionmentioning

confidence: 99%

“…The American Thyroid Association (ATA) guidelines state that mutational status and vascular invasion of follicular thyroid cancer are also prognostic factors 2 . However, although DTCs are generally stable or slow-growing, recurrence often develop rapidly after surgery, such that PD is problematic in some cases 8,12 . Currently, the incidence rates of structural PD and RD, and their clinicoradiological (CT) characteristics, remain poorly understood.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Reoperations for structurally persistent or recurrent disease after thyroidectomy: analysis via preoperative CT

Kim

Han

et al. 2020

Sci Rep

View full text Add to dashboard Cite

the incidence rates of structural persistent disease (pD) and recurrent disease (RD) after thyroidectomy, and their clinicoradiological (ct) characteristics, remain poorly understood. therefore, we characterized differentiated thyroid cancer (DTC) patients who underwent re-operations, with a focus on preoperative ct scans. We examined neck ct scans obtained prior to initial surgery and reoperation, and classified the disease into four categories according to the persistence/recurrence and neck dissection/non-dissection status. In total, 121 of 9,173 DTC patients underwent reoperations to treat PD or RD; the mean time to reoperation was 25.5 and 54.1 months, respectively. Of all reoperations, 19% (23/121) were performed to treat RD; 81% (98/121) were performed to treat PD. Compared to RD, PD was commonly detected in the non-dissected neck. Tumor multiplicity and the number of pathologically positive lymph nodes were greater in the non-dissected than dissected neck. A review of the CT data revealed more false-negative findings on the 60-s-versus 30-40-s-delay scans of PD patients with non-dissected necks. In conclusion, most of the reoperations performed on Dtc patients were for management of pD. improved preoperative ct assessments and initial surgery, based on the information of clinico-radiological characteristics, are required in the care of DTC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Reoperations for structurally persistent or recurrent disease after thyroidectomy: analysis via preoperative CT

Kim

Han

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Surgery and postoperative thyrotropin suppression therapy or radionuclide therapy (I 131 ) are currently the standard treatment for DTC (Haugen et al, 2016). However, approximately 30% of these patients will relapse after the standard treatment (Kim et al, 2018b). The recurrent DTC tends to lose the ability to absorb iodine, thereby losing the option of radioactive iodine therapy.…”

Section: Introductionmentioning

confidence: 99%

Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer

Dong

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Part of differentiated thyroid cancer will relapse or develop into dedifferentiated thyroid cancer after standard therapy, such as surgery or radionuclide therapy. Sorafenib (SOR) is recommended for the treatment of advanced or radioiodine-refractory thyroid cancer. The monotherapy using SOR is often hampered by its modest efficacy, serve systemic toxicity, and high occurrence of drug resistance. In order to enhance the antitumor effect of SOR and reduce its side effects, SOR and all-trans retinoic acid (ATRA), a differentiationpromoting drug, were loaded into poly(ethylene glycol)-poly(lactide-co-glycolide) (PEG-PLGA) polymer micelles in this study. The drug-loaded micelles, PM/(SOR+ATRA), exhibited relatively slow drug release and effective cell uptake. Compared with other treatment groups, the PM/(SOR+ATRA) treatment group showed the most significant antitumor effect and minimal systemic toxicity toward the FTC-133 thyroid cancer-bearing BALB/c nude mouse model. Immunofluorescence analysis confirmed that PM/(SOR +ATRA) could significantly promote apoptosis and re-differentiation of tumor cells. All the results demonstrated that polymer micelles loaded with SOR and ATRA could treat thyroid cancer more effectively and safely.

show abstract

Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration

Feng

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background: Differentiated thyroid carcinoma (DTC) accounts for the vast majority of thyroid cancer (TC) cases. The rapidly increasing incidence of TC requires the urgent identification of new diagnostic and therapeutic targets. Solute carrier family 27 member 2 (SLC27A2/FATP2) plays an essential role in lipid biosynthesis and fatty acid transport. Recent studies have confirmed its involvement in a variety of diseases, including cancer. Methods:In this study, the expression of SLC27A2 was analyzed in cancer and paracancerous tissue samples from 98 thyroid cancer patients, and we performed ROC analysis to confirm the diagnostic value. CCK8, Transwell, and other methods were used to study its effect on DTC, and the mechanism of SLC27A2 was investigated by RNA sequencing and Western blot. Results:The expression of SLC27A2 was upregulated in both DTC tissues and cell lines and was correlated with clinical progression. In vitro studies further confirmed that SLC27A2 knockdown attenuated the proliferation and invasion of DTC cells.Through RNA sequence analysis and gene set enrichment analysis, we found that the MAPK pathway is the main downstream signaling pathway for the regulation by SLC27A2. SLC27A2 affects cell proliferation and differentiation by inducing changes in the proto-oncogene C-FOS. Conclusions: Our results show that SLC27A2 plays an important role in tumor proliferation and migration, providing a new putative target for the diagnosis and treatment of TC.

show abstract

Persistent/Recurrent Differentiated Thyroid Cancer: Clinical and Radiological Characteristics of Persistent Disease and Clinical Recurrence Based on Computed Tomography Analysis

Cited by 10 publications

References 22 publications

Reoperations for structurally persistent or recurrent disease after thyroidectomy: analysis via preoperative CT

Reoperations for structurally persistent or recurrent disease after thyroidectomy: analysis via preoperative CT

Polymer Nanoformulation of Sorafenib and All-Trans Retinoic Acid for Synergistic Inhibition of Thyroid Cancer

Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration

Contact Info

Product

Resources

About